Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
BIOL BIOLASE Inc
GOEV Canoo Inc
CHE Chemed Corp
ASTA WorldFlix Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.

Closing Price
$324.21
Day's Change
-7.67 (-2.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
341.55
Day's Low
318.50
Volume
(Average)
Volume:
17,239,834

10-day average volume:
15,797,139
17,239,834

MRNA's position in the Biotechnology industry

Industry PeersMRNAALNYBMRNSRPTIONS

Summary

Company ProfileModerna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to...
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic...
Go to ALNY summary
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's...
Go to BMRN summary
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and...
Go to SRPT summary
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and...
Go to IONS summary
52-Week Change

VS. INDUSTRY
333.49%
45.43%
-1.61%
-42.81%
-27.71%
Market Cap

VS. INDUSTRY
$134.0B
$24.9B
$14.2B
$6.6B
$4.9B
Beta

VS. INDUSTRY
--
1.1
0.5
1.3
1.1
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
41.43x
--
--
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$7.0B
$687.5M
$1.9B
$600.1M
$687.7M
Profit Margin

VS. INDUSTRY
49.79%
-128.97%
-1.32%
-105.73%
-80.74%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
6,532.27%
99.18%
3.76%
33.29%
-26.88%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.